+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating camizestrant compared to standard endocrine therapy in patients with ER-positive, HER2-negative early breast cancer who have an intermediate or high risk of disease recurrence. This Phase III open-label study includes patients who have completed definitive locoregional therapy, with or without chemotherapy, and have received standard adjuvant endocrine therapy for at least 2 years and up to 5 years. The study aims to determine if camizestrant improves invasive breast cancer-free survival and other important outcomes over a long-term follow-up. Participants will be randomly assigned to receive either camizestrant orally or continue standard endocrine therapy chosen by their doctor, which may include aromatase inhibitors like exemestane, letrozole, anastrozole, or tamoxifen. Treatment in both groups will last for up to 60 months. The study allows prior use of CDK46 inhibitors and includes an open-label design where both participants and researchers know the assigned treatment. During the study, participants will be monitored with assessments including survival outcomes, disease-free survival, relapse-free survival, and overall survival for up to 10 years from the last patient randomized. Safety will be tracked through adverse event reporting, laboratory and vital signs tests, and symptom questionnaires measuring arthralgia, hot flushes, vaginal dryness, and quality of life. Pharmacokinetics will be studied up to 6 months after treatment starts. The total duration of participation can extend over many years to capture long-term results.

Age: 18Years - 130YearsAll GendersPhase 3
709 locations
P

Actively Recruiting

This research aims to understand how bariatric surgery affects mental health and hair cortisol levels in adults with morbid obesity over a three-year period. The study focuses on candidates for bariatric surgery, assessing psychological and weight-related changes, and the potential need for psychological support before and after surgery. Participants will be evaluated at five time points before surgery, 1 month, 1 year, 2 years, and 3 years afterward. Measurements include sociodemographic data, body metrics, clinical and nutritional information, lifestyle factors, hair cortisol levels, and psychological aspects like stress, impulsivity, emotional eating, and quality of life. Throughout the study, participants will undergo assessments involving questionnaires and physical measurements to monitor changes. Researchers will track outcomes such as symptom severity, stress levels, eating behavior, weight, body mass index, diet adherence, sleep, and physical activity. The total follow-up duration for each participant is three years, allowing detailed observation of mental health and physiological responses after bariatric surgery.

Age: 18Years - 70YearsAll Genders
2 locations
O

Actively Recruiting

Researchers are conducting a national, multicenter observational study called SOGUG-PRINCIS to collect and analyze data on patients with genitourinary cancers treated with recently approved drugs under routine clinical practice in Spain. This study is both retrospective and prospective, aiming to validate real-world effectiveness of these drugs and support future funding decisions. It will serve as a registry where new subprojects will open whenever new drugs receive authorization. The study follows patients who have started treatment with specific drugs funded by the Spanish National Health System, including darolutamide combined with androgen deprivation therapy and docetaxel for hormone-sensitive prostate cancer, adjuvant nivolumab after surgery for urothelial carcinoma, and enfortumab vedotin for urothelial carcinoma. All treatments follow their approved dosing and administration guidelines and standard clinical practice. Participants progress will be monitored through routine data collection to evaluate outcomes such as progression-free survival at 18 months, relapse-free survival at 24 months, and overall survival at 12 months after starting treatment. Data will be gathered from patients treated at participating centers, with follow-up continuing as per routine care. The study does not intervene in treatment decisions, which are made independently before enrollment.

Age: 18Years +All Genders
84 locations
O

Actively Recruiting

Researchers are conducting an observational, epidemiological study to understand thrombosis in patients diagnosed with cancer. This study focuses on patients who experience venous or arterial thromboembolic events, either symptomatic or incidental, occurring within a month before cancer diagnosis or any time afterward. The study collects detailed information about the characteristics and timing of these events in relation to cancer diagnosis to better understand this condition. The study does not involve any interventions or treatments, as it is non-interventional and observational. Data is gathered from multiple centers, tracking details such as the location and vessel of origin of the thromboembolic event, tumor characteristics, and treatment administered for cancer at baseline. Patients are followed up for 12 months to assess their situation and outcomes related to thrombosis and cancer. Participants are involved through data collection at baseline and follow-up visits. Researchers assess imaging-confirmed thromboembolic events using techniques like Doppler echocardiography and CT angiography. The study measures various outcomes including event diagnosis, tumor stage, timing between cancer diagnosis and thrombosis, and patient status at one year. This registry provides valuable information about cancer-associated thrombosis over time.

Age: 18Years +All Genders
48 locations
O

Actively Recruiting

This research aims to collect detailed information about patients with lung cancer and other thoracic tumors to better understand the disease and treatment outcomes. It focuses on individualizing treatment based on markers that predict response to chemotherapy and molecular inhibitors. The study addresses challenges such as poor prognosis, variability in diagnosis and treatment, and the need for improved early detection and prevention strategies across Europe and Spain. The study is observational and multicenter, gathering data both retrospectively and prospectively from patients diagnosed and treated by medical professionals including thoracic surgeons and oncologists. It includes multiple groups of patients based on the type of thoracic tumor, such as non-small cell lung cancer, small cell lung cancer, mesothelioma, thymic cancer, and carcinoid cancer. There are no experimental treatments instead, it involves comprehensive data collection on patient characteristics and treatments. Participants provide information from their medical history and treatment records over up to 10 years. Researchers study epidemiological and therapeutic factors related to thoracic tumors by reviewing clinical data. The main outcome is to describe characteristics of these tumors in Spanish patients. The study involves no interventions or medications, focusing on observation and data analysis to inform future care and research.

All AgesAll Genders
79 locations